1st production QuiremSpheres

On May 21st, the first patient dosis of QuiremSpheres was processed at RTM and then shipped to the stituto Nazionale dei Tumori hospital in Milan, Italy. There it was used for the treatment of a patient suffering from hepatocellular carcinoma (HCC). QuiremSpheres® are radioactive microspheres for SIRT and are based on the isotope holmium-166.

Voor meer informatie: http://www.quirem.com/

Other news

RTM added as distributor NeuraCeq®

Exciting news! Life Molecular Imaging’s NeuraCeq® 300 MBq/ml solution for injection (florbetaben 18F...

18F-FDOPA now available

Fluorodopa (18F) is now available for clinical studies and - with doctor's certificate - for routine...

RTM receives marketing authorisation for Fludeoxyglucose (18F)

We are happy to announce that RTM has received marketing authorization for 18F-FDG of 17 July 2018....

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...

News